Doravirine/lamivudine/tenofovir

Doravirine/lamivudine/tenofovir is a medication used for the treatment of HIV/AIDS. It is a fixed-dose combination of doravirine, lamivudine, and tenofovir disoproxil.

Etymology[edit | edit source]

The name "Doravirine" is derived from the chemical structure of the drug, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI). "Lamivudine" is derived from its chemical name, (2R-cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. "Tenofovir" is derived from its chemical name, (R)-9-(2-Phosphonylmethoxypropyl)adenine.

Medical uses[edit | edit source]

Doravirine/lamivudine/tenofovir is used in the treatment of HIV-1 infection in adults. It is recommended as an initial regimen for individuals who have no history of antiretroviral treatment and no known substitutions associated with resistance to the individual components of the drug.

Side effects[edit | edit source]

Common side effects include nausea, diarrhea, headache, fatigue, and abdominal pain. Serious side effects may include liver problems, kidney problems, and new or worsening mental health problems.

Pharmacology[edit | edit source]

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while lamivudine and tenofovir are nucleoside reverse transcriptase inhibitors (NRTIs). They work by blocking the action of reverse transcriptase, an enzyme that the HIV virus needs to reproduce itself.

History[edit | edit source]

Doravirine/lamivudine/tenofovir was approved for medical use in the United States in August 2018. It is marketed under the brand name Delstrigo by Merck & Co.

See also[edit | edit source]

Doravirine/lamivudine/tenofovir Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.